AMG 403

human anti-nerve growth factor monoclonal antibody

Networked: 1 relevant articles (1 outcomes, 1 trials/studies)

1.	Knee Osteoarthritis 10/08/2015 - "Safety, tolerability, pharmacokinetics, and efficacy of AMG 403, a human anti-nerve growth factor monoclonal antibody, in two phase I studies with healthy volunteers and knee osteoarthritis subjects."
2.	Paresthesia (Dysesthesia) 10/08/2015 - "AMG 403 appeared to be well-tolerated after single and multiple doses, except for subject-reported hyperesthesia, pain, and paresthesia (mild to moderate severity). "
3.	Pain (Aches) 10/08/2015 - "AMG 403 appeared to be well-tolerated after single and multiple doses, except for subject-reported hyperesthesia, pain, and paresthesia (mild to moderate severity). "
4.	Hyperesthesia 10/08/2015 - "AMG 403 appeared to be well-tolerated after single and multiple doses, except for subject-reported hyperesthesia, pain, and paresthesia (mild to moderate severity). "
5.	Body Weight (Weight, Body) 10/08/2015 - "Knee OA diagnosis, body weight, and anti-drug antibody development did not appear to affect AMG 403 PK. "